Raub Brock Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raub Brock Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,100	Closed	-$902K	–	68
2023 Q4	$902K	Hold	10,100	–	–	0.19%	35
2023 Q3	$738K	Hold	10,100	–	–	0.15%	34
2023 Q2	$840K	Hold	10,100	–	–	0.16%	30
2023 Q1	$770K	Buy	10,100 +6,000	+146%	+$498K	0.15%	30
2022 Q4	$340K	Buy	4,100 +600	+17%	+$48.6K	0.07%	44
2022 Q3	$278K	Buy	+3,500	New	+$295K	0.06%	52

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Raub Brock Capital Management's XBI Position: Q1 2024 in Review

Raub Brock Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 10,100 shares — an estimated $902K sold.

Raub Brock Capital Management first reported a position in XBI in Q3 2022 and held it in 6 quarters. The position peaked at $902K in Q4 2023. 782 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Raub Brock Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Raub Brock Capital Management sold 10,100 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $902K.
Raub Brock Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 6 quarters.
Raub Brock Capital Management's State Street SPDR S&P Biotech ETF position peaked at $902K in Q4 2023.
782 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Raub Brock Capital Management's 13F filing for Q1 2024, filed 18 Apr 2024.